論文

査読有り 国際誌
2018年1月18日

Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma.

Radiation oncology (London, England)
  • Katsuyuki Sakanaka
  • ,
  • Yuichi Ishida
  • ,
  • Kota Fujii
  • ,
  • Satoshi Itasaka
  • ,
  • Shin'ichi Miyamoto
  • ,
  • Takahiro Horimatsu
  • ,
  • Manabu Muto
  • ,
  • Takashi Mizowaki

13
1
開始ページ
7
終了ページ
7
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1186/s13014-018-0957-6

BACKGROUND: The aim of this study was to identify the long-term clinical outcome of definitive radiotherapy using three-dimensional conformal radiotherapy (3DCRT) for cervical esophageal squamous cell carcinoma (CESCC). METHODS: We retrospectively reviewed the medical records of 30 patients with CESCC [clinical stage I/II/III/IV(M1LYM); 3/2/12/13] (TNM 7th edition) who underwent definitive radiotherapy using 3DCRT between 2000 and 2014 in our institution. The median prescribed dose for the gross tumor and metastatic lymph nodes was 60 Gy. Twenty-six patients underwent elective nodal irradiation for the neck node levels III, IV, and VI and for upper mediastinal lymph nodes with a median dose of 40 Gy. Twenty-six patients underwent concurrent chemotherapy. Initial disease progression sites, locoregional control (LRC) rate, overall survival (OS) rate, and toxicities were retrospectively evaluated. A univariate analysis was performed to identify prognostic factors. RESULTS: With a median follow-up of 110 months, the 5- and 10-year LRC rates were 43.7% and 37.4%, respectively. The 5- and 10-year OS rates were 48.3% and 40.2%, respectively. Locoregional, distant and both area accounted for 83%, 6% and 11% of the initial progression sites. Unresectable status and M1LYM were significantly associated with poor LRC (p < 0.05) and OS (p < 0.05). Grade 3 acute non-hematological toxicity occurred in 13.3% of patients. During the follow-up, patients without any disease progression did not need a permanent gastrostomy tube or tracheostomy. Late toxicity events, including hypothyroidism and cardiovascular disease, were observed; 5- and 10-year cumulative incidence rates of grade 2 hypothyroidism and ≥grade 3 cardiovascular disease were 31.6% and 62.5%, and 17.5% and 21.3%, respectively. CONCLUSIONS: Definitive radiotherapy yields a cure for patients with CESCC while preserving their laryngopharyngeal function. The poor LRC rate in the advanced stage needs to be overcome for a better prognosis. As the incidence of radiation-induced hypothyroidism and cardiovascular disease was not low, long-term survivors should be followed up for these symptoms.

リンク情報
DOI
https://doi.org/10.1186/s13014-018-0957-6
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29347960
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774094
ID情報
  • DOI : 10.1186/s13014-018-0957-6
  • PubMed ID : 29347960
  • PubMed Central 記事ID : PMC5774094

エクスポート
BibTeX RIS